<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Aldous SG</submitter><funding>UK Dementia Research Institute</funding><funding>Medical Research Council</funding><funding>NCI NIH HHS</funding><funding>CHDI Foundation</funding><funding>Dementia Research Institute Ltd</funding><funding>Alzheimer’s Society and Alzheimer’s Research UK</funding><funding>NIH</funding><funding>Wellcome Trust</funding><funding>NIH HHS</funding><pagination>1784-1798</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11068328</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>147(5)</volume><pubmed_abstract>The Huntington's disease mutation is a CAG repeat expansion in the huntingtin gene that results in an expanded polyglutamine tract in the huntingtin protein. The CAG repeat is unstable and expansions of hundreds of CAGs have been detected in Huntington's disease post-mortem brains. The age of disease onset can be predicted partially from the length of the CAG repeat as measured in blood. Onset age is also determined by genetic modifiers, which in six cases involve variation in DNA mismatch repair pathways genes. Knocking-out specific mismatch repair genes in mouse models of Huntington's disease prevents somatic CAG repeat expansion. Taken together, these results have led to the hypothesis that somatic CAG repeat expansion in Huntington's disease brains is required for pathogenesis. Therefo</pubmed_abstract><journal>Brain : a journal of neurology</journal><pubmed_title>A CAG repeat threshold for therapeutics targeting somatic instability in Huntington's disease.</pubmed_title><pmcid>PMC11068328</pmcid><funding_grant_id>UKDRI-1008/1</funding_grant_id><funding_grant_id>P30 CA013330</funding_grant_id><funding_grant_id>5P30CA13330</funding_grant_id><funding_grant_id>R01 CA248536</funding_grant_id><funding_grant_id>R01CA248536</funding_grant_id><funding_grant_id>223082/Z/21/Z</funding_grant_id><pubmed_authors>Phillips J</pubmed_authors><pubmed_authors>Landles C</pubmed_authors><pubmed_authors>Bates GP</pubmed_authors><pubmed_authors>Smith EJ</pubmed_authors><pubmed_authors>Greene JR</pubmed_authors><pubmed_authors>Benn CL</pubmed_authors><pubmed_authors>Osborne GF</pubmed_authors><pubmed_authors>Jin B</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Hirst MB</pubmed_authors><pubmed_authors>Edelmann W</pubmed_authors><pubmed_authors>Canibano-Pico M</pubmed_authors><pubmed_authors>Aldous SG</pubmed_authors><pubmed_authors>Nita IM</pubmed_authors><pubmed_authors>Bond BC</pubmed_authors></additional><is_claimable>false</is_claimable><name>A CAG repeat threshold for therapeutics targeting somatic instability in Huntington's disease.</name><description>The Huntington's disease mutation is a CAG repeat expansion in the huntingtin gene that results in an expanded polyglutamine tract in the huntingtin protein. The CAG repeat is unstable and expansions of hundreds of CAGs have been detected in Huntington's disease post-mortem brains. The age of disease onset can be predicted partially from the length of the CAG repeat as measured in blood. Onset age is also determined by genetic modifiers, which in six cases involve variation in DNA mismatch repair pathways genes. Knocking-out specific mismatch repair genes in mouse models of Huntington's disease prevents somatic CAG repeat expansion. Taken together, these results have led to the hypothesis that somatic CAG repeat expansion in Huntington's disease brains is required for pathogenesis. Therefo</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 May</publication><modification>2026-06-03T20:04:00.054Z</modification><creation>2026-05-01T03:10:44.914Z</creation></dates><accession>S-EPMC11068328</accession><cross_references><pubmed>38387080</pubmed><doi>10.1093/brain/awae063</doi></cross_references></HashMap>